Quidel, a rapid diagnostic testing solutions and cell-based virology assays provider, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Sofia analyser and Sofia Influenza A+B Fluorescent Immunoassay (FIA).

The Influenza A+B FIA utilises lateral flow and immunofluorescence technologies to provide clinical sensitivity for influenza A and B.

The Sofia analyser can be installed in laboratories, hospitals, medical centres, and small clinics.

The results are readily available on the instrument’s screen, in a hard-copy printout, as well as in electronic form that can network via an LIS system to hospital and medical centre databases.

The company said both the Sofia analyser and the Influenza A+B FIA have received the CE Mark in August 2011.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.